NASDAQ:GLMD - Galmed Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 648.30 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$2.94
▼ -0.02 (-0.68%)

This chart shows the closing price for GLMD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Galmed Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GLMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GLMD

Analyst Price Target is $22.00
▲ +648.30% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Galmed Pharmaceuticals in the last 3 months. The average price target is $22.00, with a high forecast of $33.00 and a low forecast of $14.00. The average price target represents a 648.30% upside from the last price of $2.94.

This chart shows the closing price for GLMD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Galmed Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2021Canaccord GenuityBoost Price TargetBuy$20.00 ➝ $21.00Low
3/19/2021HC WainwrightLower Price TargetBuy$29.00 ➝ $25.00High
1/8/2021Raymond JamesLower Price TargetOutperform$20.00 ➝ $17.00Low
11/25/2020Canaccord GenuityLower Price TargetBuy$25.00 ➝ $20.00Low
11/13/2020Cantor FitzgeraldReiterated RatingOverweightMedium
7/12/2020Roth CapitalReiterated RatingBuy ➝ Market Perform$33.00High
7/12/2020Cantor FitzgeraldReiterated RatingOverweight$14.00High
5/22/2020B. RileyDowngradeBuy ➝ Neutral$11.00 ➝ $8.00Low
5/15/2020Maxim GroupInitiated CoverageBuy$10.00Medium
5/15/2020Raymond JamesLower Price TargetOutperform$25.00 ➝ $20.00Low
5/15/2020Canaccord GenuityReiterated RatingBuyLow
5/15/2020HC WainwrightLower Price TargetBuy$34.00 ➝ $29.00Low
3/16/2020Canaccord GenuityReiterated RatingBuyLow
3/13/2020HC WainwrightReiterated RatingBuyMedium
3/13/2020Stifel NicolausLower Price TargetBuy$35.00 ➝ $25.00Medium
3/13/2020B. RileyLower Price TargetBuy$28.00 ➝ $11.00High
2/4/2020Craig HallumInitiated CoverageBuy$18.00High
1/30/2020Cantor FitzgeraldLower Price TargetOverweight$59.00 ➝ $14.00High
12/2/2019Canaccord GenuityInitiated CoverageBuyHigh
11/7/2019Maxim GroupReiterated RatingBuy$10.00Medium
10/18/2019Cantor FitzgeraldReiterated RatingOverweightLow
8/6/2019Maxim GroupReiterated RatingBuy$20.00Medium
8/6/2019HC WainwrightReiterated RatingBuyMedium
7/22/2019LaidlawInitiated CoverageBuy$25.00High
5/8/2019HC WainwrightReiterated RatingBuy$28.00Low
5/7/2019Maxim GroupReiterated RatingBuy$20.00High
3/14/2019HC WainwrightReiterated RatingBuyMedium
3/13/2019Cantor FitzgeraldReiterated RatingBuy$59.00High
2/19/2019Cantor FitzgeraldReiterated RatingBuy$59.00Low
1/14/2019HC WainwrightLower Price TargetBuy$28.00Medium
12/11/2018B. RileyInitiated CoverageBuy ➝ Buy$28.00High
11/13/2018Maxim GroupSet Price TargetBuy$20.00High
11/5/2018Cantor FitzgeraldSet Price TargetBuy$59.00High
10/2/2018Cantor FitzgeraldSet Price TargetBuy$59.00Medium
8/7/2018Cantor FitzgeraldSet Price TargetBuy$59.00Medium
8/2/2018Maxim GroupLower Price TargetBuy$30.00 ➝ $27.00High
7/20/2018Raymond JamesInitiated CoverageOutperform$26.00High
7/13/2018Stifel NicolausInitiated CoverageBuy$35.00Medium
7/12/2018Cantor FitzgeraldReiterated RatingOverweightLow
7/12/2018Imperial CapitalInitiated CoverageOutperform$59.00High
7/11/2018Cantor FitzgeraldInitiated CoverageBuy$59.00High
6/12/2018Maxim GroupBoost Price TargetBuy ➝ Buy$14.00 ➝ $30.00High
6/12/2018SunTrust BanksBoost Price Target$15.00 ➝ $31.00High
6/12/2018HC WainwrightBoost Price TargetBuy$24.00 ➝ $43.00N/A
5/9/2018Maxim GroupSet Price TargetBuy$14.00Low
4/3/2018Maxim GroupSet Price TargetBuy$14.00High
3/27/2018Maxim GroupSet Price TargetBuy$14.00High
3/15/2018Maxim GroupUpgradeHold ➝ Buy$14.00Low
2/14/2018Maxim GroupDowngradeBuy ➝ HoldHigh
2/12/2018HC WainwrightBoost Price TargetBuy ➝ Buy$18.00 ➝ $24.00Low
1/3/2018Maxim GroupSet Price TargetBuy$14.00Low
12/6/2017Maxim GroupSet Price TargetBuy$14.00Low
11/15/2017Roth CapitalInitiated CoverageBuy ➝ Buy$32.00N/A
11/10/2017HC WainwrightReiterated RatingBuy$18.00N/A
11/9/2017Maxim GroupReiterated RatingBuy$14.00N/A
10/27/2017HC WainwrightReiterated RatingBuy$18.00N/A
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$19.00N/A
10/5/2017Maxim GroupSet Price TargetBuy$14.00N/A
8/8/2017HC WainwrightBoost Price TargetBuy ➝ Buy$12.00 ➝ $18.00High
7/31/2017Maxim GroupReiterated RatingBuy ➝ Buy$9.00 ➝ $14.00Medium
5/15/2017Maxim GroupSet Price TargetBuy$9.00Low
4/5/2017Maxim GroupSet Price TargetBuy$9.00Low
3/28/2017HC WainwrightLower Price TargetBuy$13.00 ➝ $12.00Medium
3/24/2017Maxim GroupReiterated RatingBuy$9.00Low
11/7/2016HC WainwrightReiterated RatingBuyN/A
8/5/2016(FBRC)Set Price TargetBuy$20.00N/A
8/1/2016Maxim GroupReiterated RatingBuy$24.00 ➝ $9.00N/A
7/6/2016Roth CapitalReiterated RatingBuy$6.00N/A
6/30/2016HC WainwrightReiterated RatingBuyN/A
(Data available from 6/21/2016 forward)
Galmed Pharmaceuticals logo
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol; and a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Read More

Today's Range

Now: $2.94
Low: $2.86
High: $2.94

50 Day Range

MA: $2.96
Low: $2.24
High: $3.90

52 Week Range

Now: $2.94
Low: $2.15
High: $6.29

Volume

432 shs

Average Volume

362,839 shs

Market Capitalization

$73.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Galmed Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Galmed Pharmaceuticals in the last year: Canaccord Genuity, Cantor Fitzgerald, HC Wainwright, Raymond James, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for GLMD.

What is the current price target for Galmed Pharmaceuticals?

5 Wall Street analysts have set twelve-month price targets for Galmed Pharmaceuticals in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 648.3%. Roth Capital has the highest price target set, predicting GLMD will reach $33.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $14.00 for Galmed Pharmaceuticals in the next year.
View the latest price targets for GLMD.

What is the current consensus analyst rating for Galmed Pharmaceuticals?

Galmed Pharmaceuticals currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GLMD will outperform the market and that investors should add to their positions of Galmed Pharmaceuticals.
View the latest ratings for GLMD.

What other companies compete with Galmed Pharmaceuticals?

How do I contact Galmed Pharmaceuticals' investor relations team?

Galmed Pharmaceuticals' physical mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company's listed phone number is 972-3693-8448 and its investor relations email address is [email protected] The official website for Galmed Pharmaceuticals is www.galmedpharma.com.